Compare KYN & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KYN | RXRX |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | N/A | 2021 |
| Metric | KYN | RXRX |
|---|---|---|
| Price | $12.37 | $4.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 561.5K | ★ 23.2M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 8.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | ★ $43,689,000.00 |
| Revenue This Year | N/A | $6.74 |
| Revenue Next Year | N/A | $34.31 |
| P/E Ratio | $13.79 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.84 | $3.79 |
| 52 Week High | $9.88 | $12.36 |
| Indicator | KYN | RXRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.36 | 39.19 |
| Support Level | $12.01 | $4.18 |
| Resistance Level | $12.23 | $4.43 |
| Average True Range (ATR) | 0.19 | 0.24 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 98.87 | 0.00 |
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.